Tag Archives: value-based pricing

Innovation Drops Down NICE’s Value Agenda

Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions. Omar Ali, a UK formulary development pharmacist and consultant to NICE, speaking at eyeforpharma’s Barcelona 2014 conference on Wednesday, explained that the UK price watchdog will prioritize considerations of wider societal benefit and unmet need as it […]
Posted in Europe, Events, pricing | Also tagged , , , , | Leave a comment

UK: Is Value Based Assessment the New Value Based Pricing?

NICE and Value Based Assessment: An Update By Leela Barham VBA is the new VBP The initial proposals for Value Based Pricing (VBP) have evolved into something very different.  Now there is focus on Value Based Assessment (VBA), which is really focusing on adding just two factors to the usual methods of assessing new medicines: […]
Posted in Europe, Global, Guest Blog, pricing | Also tagged , , , , , | Leave a comment

J.P. Morgan: Pharma's Agenda for 2014

Presenters at the 32nd annual J.P. Morgan Healthcare Conference talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Company executives honed in on their chosen therapeutic areas and made the case for aggressive spending in R&D to bring the next generation […]
Posted in Biotech, Corporate Responsibility, Deals, Emerging Markets, Europe, Events, FDA, Gene therapy, Global, IP, leadership, Legal, Manufacturing, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Also tagged , , , , , , , , , , , , , , , , | Leave a comment

UK: The PPRS is Dead, Long Live the PPRS!

By Leela Barham. Long awaited details have been announced in the Heads of Agreement for the latest Pharmaceutical Price Regulation Scheme (PPRS).  It’s worth a read in full (and you can find it here) but some highlights are set out here.
Posted in Global, Guest Blog, pricing, Regulatory | Also tagged , , , , | Leave a comment

Big Pharma Welcomes Extension to England's Cancer Drug Fund, Critics Unconvinced

The Cancer Drugs Fund: Extension to 2016 By Leela Barham The Cancer Drugs Fund (CDF) in England covers the cost of cancer treatments either when the National Institute for Health and Care Excellence (NICE) has said ‘no’, or hasn’t yet come to a view.  It started with £50 million and is now £200million a year. […]
Posted in Europe, Global, Guest Blog, Op-Ed | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta